Prior Authorization requirements for Continuous Interstitial Glucose Monitoring

On **August 1, 2017**, Anthem Blue Cross prior authorization requirements will change for Continuous Interstitial Glucose Monitoring. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions, take precedence over these prior authorization rules and must be considered first when determining coverage.

Non-compliance with new requirements may result in denied claims. Prior authorization requirements will be added to the codes below:

- **A9276**: Sensor; invasive (e.g., subcutaneous), disposable, for use with interstitial continuous glucose monitoring system, 1 unit = 1 day supply
- **A9277**: Transmitter; external, for use with interstitial continuous glucose monitoring system
- **A9278**: Receiver (monitor); external, for use with interstitial continuous glucose monitoring system

Not all prior authorization requirements are listed here. Detailed prior authorization requirements are available to contracted providers by accessing the “Provider Self-Service Tool” within Availity. Non-contracted providers should contact the health plan.

Anthem Blue Cross is the trade name of Blue Cross of California: Independent licensee of the Blue Cross Association. ® ANTHEM is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross names and symbols are registered marks of the Blue Cross Association.